Multi-centered evaluation of a novel fixed-dose four-factor prothrombin complex concentrate protocol for warfarin...

Area of Science:

• Pharmacology
• Internal Medicine
• Emergency Medicine

Background:

• Warfarin reversal is critical in managing bleeding events or the need for urgent surgery.
• Standard dosing of four-factor prothrombin complex concentrate (4PCC) can be variable and costly.
• Previous studies suggest fixed-dose 4PCC efficacy, but specific patient subgroups may require dose adjustments.

Purpose of the Study:

• To validate the efficacy and safety of a novel fixed-dose 4PCC protocol for warfarin reversal.
• To compare the novel fixed-dose 4PCC regimen against standard dosing in a multi-centered observational study.

Main Methods:

• Multi-centered observational study comparing fixed-dose and standard-dose 4PCC for warfarin reversal.
• Fixed-dose: 1500 units 4PCC, increased to 2000 units for baseline INR ≥ 7.5, TBW ≥ 100 kg, or ICH.
• Primary outcome: Post-4PCC INR ≤ 1.4; secondary outcomes included target INR achievement, hospital stay, cost, and thromboembolic events.

Main Results:

• No significant difference in the primary outcome (INR ≤ 1.4) between fixed-dose (57%) and standard-dose (65%) groups (p=0.32).
• No differences observed in secondary outcomes, except for a lower cost of therapy with the fixed-dose regimen.
• The study included 75 patients in the fixed-dose group and 116 in the standard-dose group.

Conclusions:

• A fixed-dose 4PCC regimen (1500 units, with 2000 units for select patients) is as effective as standard dosing for warfarin reversal.
• The fixed-dose approach demonstrates comparable efficacy to standard dosing while being more cost-effective.
• This protocol provides a viable and economical alternative for warfarin reversal in clinical practice.